RT Journal Article
SR Electronic
T1 Longitudinal proteomic investigation of COVID-19 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.01.22281744
DO 10.1101/2022.11.01.22281744
A1 Wang, Yingrui
A1 Zhu, Qianru
A1 Sun, Rui
A1 Yi, Xiao
A1 Huang, Lingling
A1 Hu, Yifan
A1 Ge, Weigang
A1 Gao, Huanhuan
A1 Ye, Xinfu
A1 Song, Yu
A1 Shao, Li
A1 Li, Yantao
A1 Li, Jie
A1 Guo, Tiannan
A1 Shi, Junping
YR 2022
UL http://medrxiv.org/content/early/2022/11/02/2022.11.01.22281744.abstract
AB Although the development of COVID-19 vaccines has been a remarkable success, the heterogeneous individual antibody generation and decline over time are unknown and still hard to predict. In this study, blood samples were collected from 163 participants who next received two doses of an inactivated COVID-19 vaccine (CoronaVac®) at a 28-day interval. Using TMT-based proteomics, we identified 1715 serum and 7342 peripheral blood mononuclear cells (PBMCs) proteins. We proposed two sets of potential biomarkers (seven from serum, five from PBMCs) using machine learning, and predicted the individual seropositivity 57 days after vaccination (AUC = 0.87). Based on the four PBMC’s potential biomarkers, we predicted the antibody persistence until 180 days after vaccination (AUC = 0.79). Our data highlighted characteristic hematological host responses, including altered lymphocyte migration regulation, neutrophil degranulation, and humoral immune response. This study proposed potential blood-derived protein biomarkers for predicting heterogeneous antibody generation and decline after COVID-19 vaccination, shedding light on immunization mechanisms and individual booster shot planning.HighlightsLongitudinal proteomics of PBMC and serum from individuals vaccinated with CoronaVac®.Machine learning models predict neutralizing antibody generation and decline after COVID-19 vaccination.The adaptive and the innate immune responses are stronger in the seropositive groups (especially in the early seropositive group).Vaccine-induced immunity involves in lymphocyte migration regulation, neutrophil degranulation, and humoral immune response.Competing Interest StatementT.G. is a shareholder of Westlake Omics Inc. X.Yi., L.H., Y.H., W.G., X.Ye. and Y.L. are employees of Westlake Omics. The remaining authors declare no competing interests in this paper.Clinical TrialThe study was registered in the Chinese Clinical Trial Register (ChiCTR2100042717, 2021-01-26)Funding StatementThis work was supported by the National Natural Science Foundation of China (32200763), Key medical disciplines of Hangzhou, the Medical Health Science and Technology Project of Hangzhou municipal Health Commission (A20210205), the National Key R&D Program of China (2020YFE0202200). The Affiliated Drum Tower Hospital, Medical School of Nanjing University (2022-LCYJ-MS-08).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the ethical committee of the Affiliated Hospital of Hangzhou Normal University and Westlake University (Hangzhou, China). The study was registered in the Chinese Clinical Trial Register (ChiCTR2100042717), and all participants signed a written informed consent before enrolment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material. The proteomics data are deposited in ProteomeXchange Consortium (https://www.iprox.org/). Project ID: IPX0004305000. All the data will be publicly released upon publication. https://www.iprox.org/ AGC(automatic gain control)AUC(area under curve)B-H(Benjamini-Hochberg)COVID-19(coronavirus disease 2019)CV(coefficients of variance)DEPs(differentially expressed)ECM(extracellular matrix)FDR(false discovery rate)GMT(Geometric Mean Titers)GSVA(gene-set variation analysis)IFN(interferon)MALFD(metabolic associated fatty liver disease)PBMCs(peripheral blood mononuclear cells)SARS-Cov-2(severe acute respiratory syndrome coronavirus 2)SHAP(SHapley Additive exPlanations)T2DM(Type 2 diabetes mellitus)